TU-G-BRB-01: Topic Introduction: Do We Need Clinical Trials in Particle Therapy and How Can Medical Physics Support Them?

2015 ◽  
Vol 42 (6Part35) ◽  
pp. 3629-3629
Author(s):  
R. Schulte
Keyword(s):  
Clinical Trials ◽  
Medical Physics ◽  
Particle Therapy

scholarly journals An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group–Radiation Therapy Study Group

2020 ◽  
Vol 61 (6) ◽  
pp. 999-1008
Author(s):  
Teiji Nishio ◽  
Mitsuhiro Nakamura ◽  
Hiroyuki Okamoto ◽  
Satoshi Kito ◽  
Toshiyuki Minemura ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Working Group ◽  
Medical Physics ◽  
Study Group ◽  
Oncology Group ◽  
Japan Clinical Oncology Group ◽  
The Absolute ◽  
Multicenter Clinical Trials ◽  
Physical Quantities

Abstract The Japan Clinical Oncology Group–Radiation Therapy Study Group (JCOG-RTSG) has initiated several multicenter clinical trials for high-precision radiotherapy, which are presently ongoing. When conducting multi-center clinical trials, a large difference in physical quantities, such as the absolute doses to the target and the organ at risk, as well as the irradiation localization accuracy, affects the treatment outcome. Therefore, the differences in the various physical quantities used in different institutions must be within an acceptable range for conducting multicenter clinical trials, and this must be verified with medical physics consideration. In 2011, Japan’s first Medical Physics Working Group (MPWG) in the JCOG-RTSG was established to perform this medical-physics-related verification for multicenter clinical trials. We have developed an auditing method to verify the accuracy of the absolute dose and the irradiation localization. Subsequently, we credentialed the participating institutions in the JCOG multicenter clinical trials that were using stereotactic body radiotherapy (SBRT) for lungs, intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) for several disease sites, and proton beam therapy (PT) for the liver. From the verification results, accuracies of the absolute dose and the irradiation localization among the participating institutions of the multicenter clinical trial were assured, and the JCOG clinical trials could be initiated.

Particle Therapy Clinical Trials

2018 ◽  
pp. 181-192
Author(s):  
Cai Grau ◽  
Damien Charles Weber ◽  
Johannes A. Langendijk ◽  
James D. Cox ◽  
Tadashi Kamada ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Particle Therapy

scholarly journals China's Particle Therapy Equipment Market: Opportunities Outweigh Challenges

2020 ◽  
Vol 8 ◽  
Author(s):  
Zhongying Dai ◽  
Yuanyuan Ma ◽  
Qiang Li
Keyword(s):  
Medical Device ◽  
Business Strategy ◽  
High Performance ◽  
Medical Physics ◽  
Market Potential ◽  
Particle Therapy ◽  
Market Demand ◽  
Medical Device Manufacturers ◽  
Market Opportunities ◽  
Demand Information

Since 2019, China has been the second largest medical device market in the world. At present, high-end radiotherapy equipment such as particle therapy system has a huge market potential due to the grim situation of cancer prevention and control and the growth of people's wealth in China. However, China's MedTech industry, especially the particle therapy equipment field, still faces the influence of policy, fluctuation of market demand, strengthening of industry supervision, and even geopolitical realities. This paper reviews the market prospect of particle therapy medical devices from the perspective of China's medical device policy and demand information analysis, which is conducive to the research on the industrial layout of particle therapy medical physics, and also helps high-performance medical device manufacturers to expand their business visions. MedTech manufacturers should actively adjust their business strategy and implement scientific and technological innovation on the basis of compliance with industry regulatory requirements in order to seize opportunities from challenges and gain profits growth.

scholarly journals A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy

2016 ◽  
Vol 3 (3) ◽  
pp. 398-406 ◽  
Author(s):  
Bismarck C. L. Odei ◽  
Dustin Boothe ◽  
Sameer R. Keole ◽  
Carlos E. Vargas ◽  
Robert L. Foote ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Clinical Trials ◽  
Nervous System ◽  
Proton Beam ◽  
Phase Ii ◽  
Proton Beam Therapy ◽  
Primary Treatment ◽  
Particle Therapy ◽  
Phase Iii ◽  
Phase Ii Trials

Purpose: Clinical trials (CTs) in proton beam therapy (PBT) are important for determining its benefits relative to other treatments. An analysis of PBT trials is, thus, warranted to understand the current state of PBT CTs and the factors affecting current and future trials. Materials and Methods: We queried the clinicaltrials.gov Website using the search terms: proton beam therapy, proton radiation, and protons. A total of 152 PBT CTs were identified. We used χ2 analysis and logistic regression to evaluate trial characteristics. Results: Most CTs were recruiting (n = 79; 52.0%), phase II (n = 95; 62.5%), open label (n = 134; 88.2%), single-group assignment (n = 84; 55.3%), and with primary treatment endpoints of safety and efficacy (n = 94; 61.8%). The primary treatment sites included gastrointestinal (n = 32; 21.1%), central nervous system (n = 31; 20.4%), lung (n = 21; 13.8%), prostate (n = 19; 12.5%), sarcoma (n = 15; 9.9%), and others (n = 24; 15.8%). Comparison studies between radiation modalities involved PBT and intensity-modulated photon therapy (n = 11; 7.2%), PBT and general photon therapy (n = 8; 5.3%), and PBT and carbon-ion therapy (n = 7; 4.6%). The PBT CTs underwent substantial growth after 2008 but now appear to be in decline. Nongovernmental institutions, comprising university centers, hospital systems, and research groups, have funded the greatest number of CTs (n= 106; 69.7%). The National Institutes of Health (NIH) were more likely to fund CTs involving the central nervous system ( P = 0.02). Trials involving NIH funding were more likely to result in successful trial completion ( P = 0.02). Conclusion: Among PBT CTs, most were phase II trials, with a very few being phase III CTs. Funding of PBT CTs originating from industry or the NIH is limited. Recently, there has been a declining trajectory of newly initiated PBT trials. It is not yet clear whether this represents a true trend or just a pause in CT implementation. Despite multiple impediments to PBT CTs, the particle therapy community continues to work toward evidence generation.

scholarly journals Nuclear Magnetic Resonance Imaging

1982 ◽  
Vol 35 (6) ◽  
pp. 761 ◽  
Author(s):  
JM Pope
Keyword(s):  
Magnetic Resonance Imaging ◽  
Nuclear Magnetic Resonance ◽  
Clinical Trials ◽  
Magnetic Resonance ◽  
Medical Physics ◽  
Nmr Imaging ◽  
Resonance Imaging ◽  
New Techniques ◽  
Nmr Methods ◽  
Nuclear Magnetic

The principles of two new techniques of medical physics, nuclear magnetic resonance (NMR) imaging and topical magnetic resonance, are outlined. Progress in the development of these techniques and their application in clinical trials is reviewed. Advantages of NMR methods over existing imaging modalities are discussed. Finally some safety aspects are considered.

Development of actual measurement-based RBE calculation model for carbon beam therapy and high-precision clinical analysis

Impact ◽  
2021 ◽  
Vol 2021 (6) ◽  
pp. 12-14
Author(s):  
Ryosuke Kohno
Keyword(s):  
Early Stage ◽  
Medical Physics ◽  
Treatment Options ◽  
Proton Beam Therapy ◽  
Clinical Analysis ◽  
Fine Tuning ◽  
Particle Therapy ◽  
Surrounding Tissue ◽  
Surgical Removal ◽  
Actual Measurement

Cancer can reduce quality of life, place strain on families and even kill. Treatment methods are not always effective nor precise and involve either surgical removal of cancerous tissues or a combination of drugs and radiation. Advances in physics are providing new hope for treatment options in the form of radiation and, specifically, particle therapy, which includes proton beam therapy and carbon ion radiotherapy (CIRT). This improves treatment precision as the beam can be targeted so that it kills cancer and not the surrounding tissue. Ryosuke Kohno, Department of Accelerator and Medical Physics, National Institutes for Quantum and Radiological Science and Technology, Japan, is interested in how applied physics can bridge with medicine, becoming medical physics. He has developed several beam therapies protocols over the years and is particularly interested in CIRT and how the technique can be improved. Kohno is currently working on fine tuning a model that can be optimally calibrated to attack all types of tumours. He and his team are also working on Intensity-Modulated Composite Particle Therapy (IMPACT). Kohno is collaborating with a multidisciplinary radiotherapy team and his interdisciplinary research involves the integration of radiation/medical physics, radiation biology and radiation oncology. He is also assisting early-stage researchers so that the next-generation of researchers can form new bridges between basic science and medicine.

203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer

2020 ◽  
Vol 27 (41) ◽  
pp. 7003-7031
Author(s):  
Mengshi Li ◽  
Edwin A. Sagastume ◽  
Dongyoul Lee ◽  
Daniel McAlister ◽  
Anthony J. DeGraffenreid ◽  
...  
Keyword(s):  
Alpha Particle ◽  
Clinical Studies ◽  
Radionuclide Therapy ◽  
Cell Damage ◽  
Medical Physics ◽  
Alpha Particles ◽  
Particle Therapy ◽  
Dna Breaks ◽  
Beta Particles ◽  
Image Guided

Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage. Recent clinical studies provide compelling evidence that alpha-TRT has the potential to deliver a significantly more potent anti-cancer effect compared with beta-TRT. Generator-produced 212Pb (which decays to alpha emitters 212Bi and 212Po) is a particularly promising radionuclide for receptor-targeted alpha-particle therapy. A second attractive feature that distinguishes 212Pb alpha-TRT from other available radionuclides is the possibility to employ elementallymatched isotope 203Pb as an imaging surrogate in place of the therapeutic radionuclide. As direct non-invasive measurement of alpha-particle emissions cannot be conducted using current medical scanner technology, the imaging surrogate allows for a pharmacologically-inactive determination of the pharmacokinetics and biodistribution of TRT candidate ligands in advance of treatment. Thus, elementally-matched 203Pb labeled radiopharmaceuticals can be used to identify patients who may benefit from 212Pb alpha-TRT and apply appropriate dosimetry and treatment planning in advance of the therapy. In this review, we provide a brief history on the use of these isotopes for cancer therapy; describe the decay and chemical characteristics of 203/212Pb for their use in cancer theranostics and methodologies applied for production and purification of these isotopes for radiopharmaceutical production. In addition, a medical physics and dosimetry perspective is provided that highlights the potential of 212Pb for alpha-TRT and the expected safety for 203Pb surrogate imaging. Recent and current preclinical and clinical studies are presented. The sum of the findings herein and observations presented provide evidence that the 203Pb/212Pb theranostic pair has a promising future for use in radiopharmaceutical theranostic therapies for cancer.

SU-F-P-13: NRG Oncology Medical Physics Manpower Survey Quantifying Support Demands for Multi Institutional Clinical Trials

2016 ◽  
Vol 43 (6Part5) ◽  
pp. 3360-3361
Author(s):  
J Monroe ◽  
K Boparai ◽  
Y Xiao ◽  
D Followill ◽  
J Galvin ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Medical Physics

scholarly journals NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery

2020 ◽  
Vol 10 ◽  
Author(s):  
Mikhail Chetvertkov ◽  
James Ira Monroe ◽  
Jaskaran Boparai ◽  
Timothy D. Solberg ◽  
Deanna H. Pafundi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Technology Use ◽  
Medical Physics ◽  
Volumetric Modulated Arc Therapy ◽  
Target Volume ◽  
Motion Management ◽  
Lung Sbrt ◽  
Policies And Procedures ◽  
Delivery Technique ◽  
Set Up

PurposeTo assess stereotactic radiotherapy (SRT)/stereotactic body radiotherapy (SBRT) practices by polling clinics participating in multi-institutional clinical trials.MethodsThe NRG Oncology Medical Physics Subcommittee distributed a survey consisting of 23 questions, which covered general technologies, policies, and procedures used in the Radiation Oncology field for the delivery of SRT/SBRT (9 questions), and site-specific questions for brain SRT, lung SBRT, and prostate SBRT (14 questions). Surveys were distributed to 1,996 radiotherapy institutions included on the membership rosters of the five National Clinical Trials Network (NCTN) groups. Patient setup, motion management, target localization, prescriptions, and treatment delivery technique data were reported back by 568 institutions (28%).Results97.5% of respondents treat lung SBRT patients, 77.0% perform brain SRT, and 29.1% deliver prostate SBRT. 48.8% of clinics require a physicist present for every fraction of SBRT, 18.5% require a physicist present for the initial SBRT fraction only, and 14.9% require a physicist present for the entire first fraction, including set-up approval for all subsequent fractions. 55.3% require physician approval for all fractions, and 86.7% do not reposition without x-ray imaging. For brain SRT, most institutions (83.9%) use a planning target volume (PTV) margin of 2 mm or less. Lung SBRT PTV margins of 3 mm or more are used in 80.6% of clinics. Volumetric modulated arc therapy (VMAT) is the dominant delivery method in 62.8% of SRT treatments, 70.9% of lung SBRT, and 68.3% of prostate SBRT.ConclusionThis report characterizes SRT/SBRT practices in radiotherapy clinics participating in clinical trials. Data made available here allows the radiotherapy community to compare their practice with that of other clinics, determine what is achievable, and assess areas for improvement.

Sign in / Sign up

Export Citation Format

Share Document